📣 VC round data is live. Check it out!

Tempus AI Valuation Multiples

Discover Tempus AI's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like SenseTime Group, ICON plc, Revvity, UiPath and more.

Tempus AI Overview

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.


Founded

2015

HQ

United States

Employees

3.8K

Website

tempus.com

Financials (LTM)

Revenue: $1B
EBITDA: $22M

EV

$10B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tempus AI Financials

Tempus AI reported last 12-month revenue of $1B and EBITDA of $22M.

In the same LTM period, Tempus AI generated $896M in gross profit, $22M in EBITDA, and had net loss of ($287M).

Revenue (LTM)


Tempus AI P&L

In the most recent fiscal year, Tempus AI reported revenue of $1B and EBITDA of ($7M).

Tempus AI is unprofitable as of last fiscal year, with gross margin of 63%, EBITDA margin of (1%), and net margin of (19%).

See analyst estimates for Tempus AI
LTMLast FY202320242025202620272028
Revenue$1B$1B$532M$693M$1B
Gross Profit$896M$798M$286M$381M$798M
Gross Margin64%63%54%55%63%
EBITDA$22M($7M)($133M)($610M)($119M)
EBITDA Margin2%(1%)(25%)(88%)(9%)
EBIT Margin(2%)(4%)(37%)(100%)(20%)
Net Profit($287M)($245M)($214M)($706M)($245M)
Net Margin(20%)(19%)(40%)(102%)(19%)
Net Debt-$635M---

Financial data powered by Morningstar, Inc.

Tempus AI Stock Performance

Tempus AI has current market cap of $9B, and enterprise value of $10B.

Market Cap Evolution


Tempus AI's stock price is $52.80.

Tempus AI share price increased by 4.6% in the last 30 days, and decreased by 16.9% in the last year.

Tempus AI has an EPS (earnings per share) of $-1.36.

See more trading valuation data for Tempus AI
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$10B$9B4.6%4.6%16.8%-16.9%$-1.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tempus AI Valuation Multiples

Tempus AI trades at 7.2x EV/Revenue multiple, and 460.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Tempus AI

EV / Revenue (LTM)


Tempus AI Financial Valuation Multiples

As of June 2, 2026, Tempus AI has market cap of $9B and EV of $10B.

Tempus AI has a P/E ratio of (33.0x).

LTMLast FY202320242025202620272028
EV/Revenue7.2x8.0x19.1x14.7x8.0x
EV/EBITDAn/mn/m(76.2x)(16.6x)(85.7x)
EV/EBITn/m(215.4x)(51.8x)(14.7x)(40.2x)
EV/Gross Profit11.3x12.7x35.5x26.7x12.7x
P/E(33.0x)(38.7x)(44.3x)(13.4x)(38.7x)
EV/FCF113.7x54.4x(40.8x)(48.1x)(41.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tempus AI Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Tempus AI Margins & Growth Rates

Tempus AI grew revenue by 25% but EBITDA decreased by 952% in the last fiscal year.

In the most recent fiscal year, Tempus AI reported gross margin of 63%, EBITDA margin of (1%), and net margin of (19%).

See estimated margins and future growth rates for Tempus AI

Tempus AI Margins

Last FY202420252026202720282029
Gross Margin63%55%63%64%
EBITDA Margin(1%)(88%)(9%)4%
EBIT Margin(4%)(100%)(20%)(1%)
Net Margin(19%)(102%)(19%)(22%)
FCF Margin15%(30%)(19%)(3%)

Tempus AI Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth25%30%83%25%
Gross Profit Growth28%33%109%28%
EBITDA Growth(952%)358%(81%)(153%)
EBIT Growth(67%)252%(63%)(94%)
Net Profit Growth41%230%(65%)41%
FCF Growth(125%)(15%)16%(81%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Tempus AI Operational KPIs

Tempus AI's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Tempus AI's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tempus AI's Rule of X is 67% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Tempus AI
LTMLast FY202320242025202620272028
Rule of 4025%29%---
Bessemer Rule of X61%67%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.3M---
G&A Expenses to Revenue46%46%--46%
R&D Expenses to Revenue13%25%35%46%25%
Opex to Revenue-83%91%155%83%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SenseTime Group10.7x9.7x(252.2x)(68.5x)
ICON plc1.6x1.7x8.8x9.3x
Revvity4.8x4.8x16.2x15.8x
UiPath3.5x3.4x14.8x13.8x
Solventum2.1x2.2x7.0x9.5x
Presight AI5.7x5.1x21.8x19.7x
Hinge Health7.8x6.8x38.0x28.6x
Caris Life Sciences5.2x4.8x30.9x29.2x

This data is available for Pro users. Sign up to see all Tempus AI competitors and their valuation data.

Start Free Trial

Tempus AI VC Funding History

Before going public, Tempus AI raised $910M in total equity funding, across 10 rounds.

Last private valuation of Tempus AI was $10B, after raising $100M in October 2022.


Tempus AI Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-22Undisclosed stage-$100M$10BTempus is an artificial intelligence company specializing in precision medicine and healthcare advancement. Founded in 2015 by Eric Lefkofsky, the company operates a disease-agnostic platform that aggregates de-identified clinical and molecular data to develop AI-enabled diagnostics and insights for personalized patient care across oncology, neuropsychiatry, infectious disease, and cardiology. In October 2022, Tempus announced $275 million in additional funding comprised of equity from existing investors and debt financing from funds managed by Ares Management, bringing total funding raised to over $1.3 billion across 13 rounds. The October 2022 round valued the company at approximately $10 billion post-money, based on the stated pricing relative to the previous fundraising round. For the full year 2023 (the most recent complete fiscal year prior to the current date), Tempus generated revenue of $531.8 million and reported adjusted EBITDA of negative $154.2 million, reflecting the company's continued investment in scaling operations and AI model development. The company later went public via IPO, trading at a market cap of approximately $7 billion post-IPO, and by January 2026 reported record total contract value exceeding $1.1 billion and full year 2025 revenue of approximately $316 million with 31% year-over-year growth, though this post-IPO performance is outside the scope of the October 2022 funding round being evaluated.
Dec-20Series GBaillie Gifford; Eric Lefkofsky; Putnam Premier IT; Alphabet; Novo Holdings; T. Rowe Price$200M$8BTempus is a Chicago-based health technology company founded in 2015 by Eric Lefkofsky, specializing in precision medicine through artificial intelligence, machine learning, and vast libraries of clinical and molecular data. The platform analyzes multimodal data including gene sequencing, electronic health records, and outcomes to enable physicians to deliver personalized patient care, particularly in oncology, while also licensing anonymized data to pharmaceutical companies, researchers, and government for drug discovery and clinical trials. Tempus claims to hold one of the world's largest such data libraries, having analyzed data from a third of U.S. cancer patients and partnering with thousands of oncologists across major medical systems like Northwestern University and the University of Chicago. In December 2020, Tempus raised $200 million in a Series G round led by Google, with participation from Novo Holdings, Baillie Gifford, Franklin Templeton, T. Rowe Price, and others including Putnam-related entities, achieving a post-money valuation of $8.1 billion. This followed a $100 million Series G tranche in March 2020 at $5 billion valuation, bringing total funding to over $1.05 billion. The funds supported scaling clinical data infrastructure, enhancing AI models, expanding into cardiology, infectious diseases, depression, and diabetes, and commercialization efforts amid COVID-19 testing partnerships with CVS Health and Yale. The round positioned Tempus as Chicago's most valuable startup at the time, with ambitions to become central infrastructure for data-driven medicine.
Mar-20Series GBaillie Gifford; New Enterprise Associates; Novo Holdings; T. Rowe Price$100M$5B-
May-19Series FBaillie Gifford; New Enterprise Associates; Novo Holdings; Revolution; Revolution Growth$200M$3BTempus is an artificial intelligence-driven precision medicine company founded in September 2015 by Eric Lefkofsky that uses advanced machine learning, next-generation sequencing, and AI-assisted image recognition to analyze clinical and molecular data. The platform helps physicians make real-time, data-driven treatment decisions for individual patients, with an initial focus on cancer but expanding into multiple therapeutic areas. The company has built one of the largest connected clinical and genomic databases aggregated from academic medical centers, community-based hospitals, and healthcare networks across the United States, touching more than one in four cancer patients in the country. On May 30, 2019, Tempus announced a $200 million Series F financing round at a $3.1 billion post-money valuation. The round was led by investors including Baillie Gifford, Franklin Templeton, New Enterprise Associates (NEA), Novo Holdings, Revolution Growth, and funds managed by T. Rowe Price. This represented a significant increase from the Series E round in August 2018, which was announced at a $2 billion valuation and raised $110 million. With the Series F close, Tempus had raised $520 million in total funding since its founding. The company stated it would use the additional funds to enhance operations and accelerate expansion into new therapeutic areas and geographies. By May 2019, Tempus had built what the company described as "the most comprehensive data set in the industry" powered by partnerships with leading academic medical centers, NCI-designated cancer centers, hospital networks, and researchers, including partnerships with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology (ASCO). The platform's capabilities enabled the company to serve the entire healthcare ecosystem including providers, payers, researchers, and life sciences companies with real-world clinical evidence connected to rich molecular data to improve patient care outcomes.
Aug-18Series EBaillie Gifford; New Enterprise Associates; Revolution; Revolution Growth; T. Rowe Price$110M$2B-
Mar-18Series DNew Enterprise Associates; Revolution; Revolution Growth; T. Rowe Price$80M$1BTempus is a Chicago-based technology company advancing precision medicine by building the world's largest library of molecular and clinical data, providing genomic sequencing services, and offering an AI-powered platform for physicians to make data-driven decisions, primarily in oncology but expanding to other areas. The $80M financing round in March 2018, described as additional funding, included existing investors New Enterprise Associates and Revolution Growth, plus new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, bringing total funding to $210M at that point; funds were earmarked to grow and scale its clinical and molecular analytic platform. This round preceded the August 2018 Series E of $110M at a $2B valuation, led by Baillie Gifford with participation from T. Rowe Price, Revolution Growth, NEA, pushing total funding to $320M. The company had grown rapidly, employing around 500 people, relocating to larger offices, and partnering with entities like CancerLinQ (ASCO subsidiary), leading academic centers, NCI-designated cancer centers, and community physicians, with its platform touching nearly 1 in 4 U.S. cancer patients by mid-2018. Tempus leverages machine learning, next-generation sequencing, and AI for insights, aiming to extend into Europe, Asia, Australia, and non-oncology areas like cardiovascular disease and diabetes using Series E proceeds. Traction highlights include collaborations with Cleveland Clinic, Mayo Clinic, University of Michigan Comprehensive Cancer Center, and Penn Medicine, positioning Tempus as one of Chicago's few unicorns alongside firms like Avant and Uptake.
Sep-17Series CNew Enterprise Associates; Revolution; Revolution Growth$70M$700MTempus is a Chicago-based precision medicine company founded in 2015 by Eric Lefkofsky, leveraging AI and massive clinical and molecular data to enable physicians to make data-driven oncology treatment decisions. Its platform integrates genomic sequencing, clinical records, and AI analytics to support personalized cancer care, drug discovery, and clinical trial matching. On September 25, 2017, Tempus announced a $70 million Series B funding round co-led by New Enterprise Associates (NEA) and Revolution (including Revolution Growth), with participation from prior investors like Revolution Ventures, Euclid Ventures, and others. The round brought total funding to over $100 million. Funds were allocated to expand its AI-enabled platform, grow its sequencing and data library, and scale operations amid surging demand for precision oncology tools. At the time, Tempus had sequenced thousands of patient samples and built one of the world's largest libraries of clinical and molecular data, positioning it as a leader in multimodal data aggregation for cancer. The company competed with firms like Foundation Medicine and Guardant Health in the precision diagnostics space. Tempus continued rapid growth post-round, launching new products and partnerships with pharma giants like Pfizer and AstraZeneca, leading to subsequent rounds including a $200M Series C in 2018 and eventual unicorn status.
Apr-17Series B-$30M-Tempus AI, founded in 2015 by Eric Lefkofsky after his wife's breast cancer diagnosis, is a Chicago-based medical data tech company using AI for precision medicine, focusing on genomic testing, molecular data analysis for cancer care, and expansion into areas like cardiology and neurology. It operates an interactive platform aggregating the world's largest clinical and molecular data libraries to enable personalized treatments for oncologists across thousands of providers. The company has raised over $1.3 billion to $3 billion across 13 rounds since inception, with key investors including Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, T. Rowe Price, Revolution, Google, and SoftBank. Notable later rounds include a $200M Series F at $2.9B pre-money valuation, $100M Series G at $5B post-money, and a Series G-5 in Apr 2024 at $8.89B valuation. Tempus went public on Nasdaq in June 2024 at $6.1B market value, raising $410.7M at $37/share. Recent financials from SEC S-1 show revenue growth from $188M in 2020 to $532M in 2023, with adjusted EBITDA losses narrowing from $(239M) in 2022 to $(154M) in 2023; Q3 2024 revenue reached $334M (up 84% YoY) driven by $1.1B total contract value from pharma deals with Pfizer, Eli Lilly, GSK, and AstraZeneca. Tempus positions itself at the intersection of AI, big data, and healthcare, competing in precision oncology and drug discovery, with traction via partnerships with major medical systems and biotechs.
Jun-16Series B-$10M-Tempus raised a Series B round of $10 million on June 1, 2016.
Sep-15Series A-$10M-Tempus, founded in September 2015 by Groupon co-founder Eric Lefkofsky, is a Chicago-based technology company advancing precision medicine through collection and analysis of molecular and clinical data, primarily for cancer patients. The company has built comprehensive datasets using machine learning, next-generation sequencing, and AI, partnering with academic medical centers, NCI-designated cancer centers, hospital networks, and CancerLinQ. Tempus has raised over $1.3 billion across multiple funding rounds since inception. In August 2018, it secured $110 million in Series E financing at a $2 billion valuation from investors including Baillie Gifford, T. Rowe Price, Revolution Growth, and NEA, bringing total funding to $320 million at that time. Subsequent rounds included a $200 million Series F in 2019 at $3.1 billion valuation and a $100 million Series G in 2020 at $5 billion post-money valuation. The company expanded beyond oncology into areas like diabetes, depression, and cardiology, claiming to serve thousands of oncologists and touch one in four U.S. cancer patients. Tempus reported revenue of $320.7 million in 2022 and $531.8 million in 2023 per its S-1 filing, with ongoing losses and plans for an IPO targeting up to $6.1 billion valuation.

Acquisitions by Tempus AI

Tempus AI has acquired 8 companies to date.

Last acquisition by Tempus AI was on August 22nd 2025. Tempus AI acquired Paige for $81M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Tempus AI

Paige
Deep 6 AI
Ambry Genetics
Dawson Forte Cashmere
Description
Paige develops AI-powered computational pathology platforms originating from Memorial Sloan Kettering Cancer Center, launched in 2017 and New York-headquartered. The technology received FDA breakthrough device designation for its prostate cancer diagnostic tool, analyzing whole-slide images to enhance pathologist accuracy and workflow efficiency. Paige processes biopsies for hospitals worldwide, integrating with lab information systems.
Deep 6 AI is a Pasadena-headquartered software platform applying artificial intelligence to accelerate clinical trial recruitment. The technology parses electronic health records, including ICD-10 codes, physician notes, pathology reports, and surgical documentation, to match patients with trials. Founded in 2016, it partners with health systems to expedite site feasibility and enrollment.
Ambry Genetics is an Irvine, California-based privately held healthcare company offering the industry's broadest genetic testing portfolio. Its solutions reach insurers covering 90 percent of U.S. patients through public and private plans. Committed to open scientific collaboration, Ambry operates a CLIA- and CAP-accredited laboratory focused on hereditary cancer, cardiology, neurology, and reproductive health testing.
Dawson Forte Cashmere is a London-based luxury retailer focused on high-quality cashmere apparel and accessories. The company sells scarves, gloves, hats, sweaters, cardigans, and throws made from 100% Mongolian cashmere sourced directly from nomadic herders in the Gobi Desert. It also provides silk-cashmere blends and merino wool knits for men and women through its e-commerce platform and physical stores in the UK.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
New York City, NY
Los Angeles, CA
Los Angeles, CA
Canton, OH
Deal Date22 Aug 20257 Mar 20256 Nov 202428 Mar 2024
Valuation$81M$17M$600Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Tempus AI acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tempus AI

When was Tempus AI founded?Tempus AI was founded in 2015.
Where is Tempus AI headquartered?Tempus AI is headquartered in United States.
How many employees does Tempus AI have?As of today, Tempus AI has over 3K employees.
Who is the CEO of Tempus AI?Tempus AI's CEO is Eric P. Lefkofsky.
Is Tempus AI publicly listed?Yes, Tempus AI is a public company listed on Nasdaq.
What is the stock symbol of Tempus AI?Tempus AI trades under TEM ticker.
When did Tempus AI go public?Tempus AI went public in 2024.
Who are competitors of Tempus AI?Tempus AI main competitors include SenseTime Group, ICON plc, Revvity, UiPath, Solventum, Presight AI, Hinge Health, Caris Life Sciences, Lemonade, XtalPi.
What is the current market cap of Tempus AI?Tempus AI's current market cap is $9B.
What is the current revenue of Tempus AI?Tempus AI's last 12 months revenue is $1B.
What is the current revenue growth of Tempus AI?Tempus AI revenue growth (NTM/LTM) is 24%.
What is the current EV/Revenue multiple of Tempus AI?Current revenue multiple of Tempus AI is 7.2x.
What is the current EBITDA of Tempus AI?Tempus AI's last 12 months EBITDA is $22M.
What is Tempus AI's EBITDA margin?Tempus AI's last 12 months EBITDA margin is 2%.
What is the current EV/EBITDA multiple of Tempus AI?Current EBITDA multiple of Tempus AI is 460.1x.
What is the current FCF of Tempus AI?Tempus AI's last 12 months FCF is $89M.
What is Tempus AI's FCF margin?Tempus AI's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of Tempus AI?Current FCF multiple of Tempus AI is 113.7x.
How many companies Tempus AI has acquired to date?As of June 2026, Tempus AI has acquired 8 companies.
What was the largest acquisition by Tempus AI?$600M acquisition of Ambry Genetics on 6th November 2024 was the largest M&A Tempus AI has done to date.
What companies Tempus AI acquired?Tempus AI acquired Ambry Genetics, Paige, Deep 6 AI, Highline Sciences, AKESOgen, Dawson Forte Cashmere, Arterys, and Mpirik.
In how many companies Tempus AI has invested to date?Tempus AI hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Tempus AI

Lists including Tempus AI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial